Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

This trial used a therapeutic hypothermia system that used balloon catheters filled with cooled saline, such as the Zoll Thermogard XP temperature management system. #ACC21 #ACC2021 #therapeutichypothermia
News | Sudden Cardiac Arrest
Lower Temperature Therapeutic Hypothermia Did Not Improve Outcomes After Cardiac Arrest

May 17, 2021 — In patients receiving therapeutic hypothermia after suffering out-of-hospital cardiac arrest, those who ...

Home May 17, 2021
Home
The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization. The findings from the VOYAGER PAD trial were presented at the American College of Cardiology (ACC) 2021 Scientific Session.
News | Peripheral Artery Disease (PAD)
Rivaroxaban Reduces First and Total Ischemic Events in Patients with Peripheral Artery Disease

May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the ...

Home May 17, 2021
Home
The FLOWER-MI trial presented at ACC 2021 found no benefit to FFR-guided PCI in STEMI with multi-vessel disease. #ACC21 #ACC2021 #FFR
News | FFR Technologies
No Benefit to FFR-guided PCI in STEMI Patients With Multi-Vessel Disease

May 17, 2021 — In patients who received a coronary stent for an ST-elevation myocardial infarction (STEMI) heart attack ...

Home May 17, 2021
Home
The Record Paradise RDN catheter uses a balloon catheter filled with water to cool the vessel wall as ultrasound-based ablation energy is delivered. It delivers a ring of ablative energy to a depth of 1-6 mm. Kirtane said it requires 2-3 sonications lasting 7 seconds each in each of the main renal arteries. #ACC21 #ACC2021 #RDN
Feature | Hypertension | By Dave Fornell, Editor
Renal Denervation Lowers Blood Pressure in Medication-Resistant Hypertension 

May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system ...

Home May 16, 2021
Home
The Boston Scientific Watchman device have performed better than expected in real-world patients outside of trials since it was introduced in 2015, according to data from the NCDR LAAO Registry. #ACC21 #ACC2021 #LAA #Watchman
Feature | Left Atrial Appendage (LAA) Occluders
NCDR LAAO Registry Shows Left Atrial Appendage Occlusion Associated With Low Rate of Stroke

May 15, 2021 - Transcatheter left atrial appendage occlusion (LAAO) with a Boston Scientific Watchman device was ...

Home May 16, 2021
Home
In the LAAOS III trial, surgeons could seal off the LAA during the open heart procedure using sutures, staples or approved closure devices. The image shows a SentraHeart lasso type LAA occluder about to seal off the LAA from the outside of the heart. #ACC21 #ACC2021
News | Left Atrial Appendage (LAA) Occluders
Left Atrial Appendage Occlusion Reduces Stroke After Heart Surgery

May 15, 2021 — Patients with an elevated risk of stroke due to heart rhythm problems, or atrial fibrillation (AFib) ...

Home May 15, 2021
Home
The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021
News | Antiplatelet and Anticoagulation Therapies
Baby and Regular Strength Aspirin Equal in Cardiac Platelet Inhibition and Safety

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
An Edward Lifesciences Sapien TAVR valve during an implant procedure on angiography. There are still questions on how to best anticoagulate TAVR patients and the ATLANTIS study found Eloquis is not a good solution.
News | Structural Heart
TAVR Anticoagulation With Apixaban Not Superior to Standard Care

May 15, 2021 — The anticoagulant apixaban (Eliquis) was not superior to standard of care following transcatheter aortic ...

Home May 15, 2021
Home
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.
Feature | Cath Lab | By Dave Fornell, Editor
Creating a Cardio-renal Program to Expand Patient Volume

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal ...

Home May 14, 2021
Home
Explaining the Emory TMVR angle. Discordance between mitral annular centerline (yellow lines) and valve orientation imposed by guidewire position within the LV apex (red dashed lines). (B) Valve intrinsic angle (α) is determined by external skirt height. (C) When annular-apical “Emory” angle (red curves) exceeds α (blue curve), annular skirt apposition is not possible, causing PVL (red arrows). (D) The valve is oriented perpendicular to the annual plane using an exteriorized apical guidewire.
Feature | Structural Heart | By Dave Fornell, Editor
The Emory Angle Can Help Eliminate Paravalvular Leak in Transcatheter Mitral Interventions

The mitral valve anatomy is extremely complex, which has caused many challenges for transcatheter mitral valve ...

Home May 13, 2021
Home
Videos | Structural Heart
VIDEO: Harmony Transcatheter Pulmonary Valve Has Good Outcomes at 1 Year

Tom Jones, M.D., director, cardiac catheterization laboratories, Seattle Children’s Hospital, and principle investigator ...

Home May 13, 2021
Home
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc
News | Cath Lab
Abbott’s New Artificial Intelligence OCT Coronary Imaging Platform Launches in Europe

May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has ...

Home May 12, 2021
Home
Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a new, low-profile thoracic aortic endograft is safe and effective in the treatment of descending thoracic aortic aneurysm or penetrating atherosclerotic ulcer (PAU) diseases.
News | Endovascular Aortic Repair
Low Profile Thoracic Aortic Endograft Device Reduces Complications and Expands Patient Pool

May 12, 2021 — Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a ...

Home May 12, 2021
Home
The digital technology is reducing reliance on unnecessary invasive diagnostic procedures and is cutting hospital waiting times
News | Artificial Intelligence
NICE Renews Support for Use of AI-powered HeartFlow Analysis

May 12, 2021 — HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced that the National ...

Home May 12, 2021
Home
The BioCardia cardiac stem cell CardiAMP trial is a Phase III study looking at the efficacy of using stem cells to improve heart function in heart failure patients. It is the first trial for this technology to reach Phase III trial.
Feature | Stem Cell Therapies | By Simon H. Stertzer, M.D.
Is Cardiac Cell Therapy Worth Another Look?

Heart failure remains an unheralded global pandemic, costing society billions of dollars each year.[1,2] Projections ...

Home May 11, 2021
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now